---
layout: post
title: "Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints To Support Accelerated Approval; Draft Guidance for Industry; Availability"
date: 2026-02-04 21:07:40 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2026-01068
original_published: 2026-01-21 00:00:00 +0000
significance: 8.00
---

# Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints To Support Accelerated Approval; Draft Guidance for Industry; Availability

**Published:** February 04, 2026 21:07 UTC
**Source:** Federal Register
**Original Published:** January 21, 2026 00:00 UTC
**Document Number:** 2026-01068

## Summary

The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled "Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval." When finalized, this guidance will provide recommendations to sponsors about using minimal residual disease (MRD) and complete response (CR) in multiple myeloma as primary endpoints in trials evaluating drug and biological products intended to treat patients with multiple myeloma to support approval under accelerated approval.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2026/01/21/2026-01068/minimal-residual-disease-and-complete-response-in-multiple-myeloma-use-as-endpoints-to-support)
- API: https://www.federalregister.gov/api/v1/documents/2026-01068

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
